Healthcare Services

Congestive Heart Failure (CHF) Market Revenue Expected to Reach $23.78 Billion by 2030 with 6.8% CAGR

March 31, 2026March 31, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Congestive Heart Failure (CHF) Market Between 2026 And 2030?

The congestive heart failure (chf) market size has shown significant expansion in recent years. It is anticipated to increase from $17.1 billion in 2025 to $18.31 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. This historical market growth can be attributed to factors like an increasing aging population, the high occurrence of cardiovascular disease, restricted outpatient monitoring choices, frequent hospital readmissions, and a reliance on hospital-based care.

The congestive heart failure (chf) market size is anticipated to experience robust expansion in the coming years. It is projected to grow to $23.79 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.8%. This growth during the forecast period can be attributed to the rising prevalence of heart failure, improved diagnostic precision, the proliferation of homecare environments, an increasing uptake of guideline-based treatments, and a strategic focus on reducing hospital readmissions. Prominent trends observed for this period include the rising adoption of combination drug therapies, a transition towards home-based heart failure management, an intensified focus on early diagnosis and continuous monitoring, the development of chronic disease management initiatives, and the broadening of post-discharge care pathways.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20730&type=smp

What Key Drivers Are Influencing The Growth Of The Congestive Heart Failure (CHF) Market?

A rising prevalence of cardiovascular patients is projected to stimulate the growth of the congestive heart failure (CHF) market moving forward. Cardiovascular relates to the heart and blood vessels, emphasizing their critical role in blood circulation and sustaining the body’s overall health. The increase in cardiovascular patients is attributable to factors like sedentary lifestyles, unhealthy dietary habits, an aging population, and urbanization, which collectively intensify the demand for advanced healthcare and treatment options. Congestive heart failure (CHF) provides crucial support for cardiovascular patients by offering targeted solutions that enhance heart efficiency, mitigate symptoms, and prevent complications, ultimately improving patient care and overall well-being. For instance, in January 2023, according to the American College of Cardiology, a US-based nonprofit medical society, cardiovascular disease cases climbed to 19.8 million in 2022. Additionally, Eastern Europe registers the highest mortality rate at 553 deaths per 100,000. Therefore, the expanding number of cardiovascular patients is propelling growth within the congestive heart failure (CHF) market.

Which Market Segments Are Examined In The Congestive Heart Failure (CHF) Market Study?

The congestive heart failure (chf) market covered in this report is segmented –

1) By Type: Systolic Heart Failure, Diastolic Heart Failure, Left-Sided Heart Failure, Right-Sided Heart Failure

2) By Treatment: Medication, Surgery

3) By Diagnosis: Electrocardiogram, Echocardiogram, Magnetic Resonance Imaging (MRI), Stress Test, Blood Tests, Cardiac Catheterization, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings

Subsegments:

1) By Systolic Heart Failure: Reduced Ejection Fraction (HFrEF), Mild-to-moderate Reduced Ejection Fraction

2) By Diastolic Heart Failure: Preserved Ejection Fraction (HFpEF), Borderline Ejection Fraction (HFpEF)

3) By Left-Sided Heart Failure: Acute Left-Sided Heart Failure, Chronic Left-Sided Heart Failure

4) By Right-Sided Heart Failure: Acute Right-Sided Heart Failure, Chronic Right-Sided Heart Failure

Which Market Trends Are Creating New Opportunities In The Congestive Heart Failure (CHF) Market?

Leading companies within the congestive heart failure (CHF) market are concentrating on advanced innovations, such as single intracoronary infusion therapies, to deliver effective treatment options that enhance heart function and improve the quality of life for CHF patients. Single intracoronary infusion involves the direct delivery of medication into the coronary artery, specifically targeting the heart to provide precise treatment for conditions like congestive heart failure (CHF). For instance, in January 2024, Bayer AG, a Germany-based pharmaceutics company, and Asklepios Biopharmaceutical, Inc., a US-based biotechnology company, initiated the GenePHIT Phase II trial for AB-1002, an investigational gene therapy for congestive heart failure (CHF). This innovation employs a gene therapy approach to target non-ischemic cardiomyopathy, potentially offering a breakthrough in CHF treatment through advanced genetic solutions. The trial is adaptive, double-blind, placebo-controlled, and aims to enroll between 90 and 150 participants who have remained medically stable for at least four weeks and have a left ventricular ejection fraction between 15% and 35%.

Who Are The Primary Competitors In The Congestive Heart Failure (CHF) Market?

Major companies operating in the congestive heart failure (chf) market are Pfizer Inc., Johnson & Johnson Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Medtronic Plc, Canon Medical Systems Corporation, Jarvik Heart Inc., Boston Scientific Corporation, Biotronik SE & Co. KG, LivaNova Plc, Edwards Lifesciences Corporation, Getinge AB, MicroPort Scientific Corporation, Lepu Medical Technology Co Ltd, OSCOR Inc., Shree Pacetronix Ltd.

Read the full congestive heart failure (chf) market report here:

https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-chf-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Congestive Heart Failure (CHF) Market?

North America was the largest region in the congestive heart failure (CHF) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure (chf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Congestive Heart Failure (CHF) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20730&type=smp

Browse Through More Reports Similar to the Global Congestive Heart Failure (CHF) Market 2026, By The Business Research Company

Congenital Heart Defect Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/congenital-heart-defect-devices-global-market-report

Cardiometabolic Diseases Global Market Report

https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

Pediatric Heart Valve Repair And Replacement Global Market Report

https://www.thebusinessresearchcompany.com/report/pediatric-heart-valve-repair-and-replacement-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795